Stock fell 7.52% in premarket trading due to dilutive public offering announcement at $29.35 per ADS. Additionally, recent earnings showed adjusted loss of 3 cents per share (wider than expected 2 cents) and revenue slightly below consensus estimates, indicating near-term headwinds despite positive long-term analyst outlook.
The company is successfully executing a substantial $226 million capital raise, demonstrating investor confidence and providing financial resources to expand its cell therapy platform, particularly for CARVYKTI commercialization and pipeline development. The offering indicates strong market positioning as the largest standalone cell therapy company.
The company announced strong Phase 1 clinical proof-of-concept data for LB2501 with 100% ORR and 83.3% CR at the higher dose level, favorable safety profile with no serious adverse events or ICANS, and successful in vivo CAR-T generation without lymphodepletion. These results represent significant progress in next-generation cell therapy and support advancement of the program.
Stock gained 18% on Monday driven by two bullish analyst reiterations with price targets of $50-$62. Analysts praised innovative CAR-T pipeline programs and upcoming trial data publication. The company's science is described as 'innovative and very promising.'
Articles that tag LEGN but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
